Spero Therapeutics, Inc.

NASDAQ:SPRO

Biotechnology

Healthcare
$0.87 +3.79%

+$0.08 today

Market cap
$50.92M
Beta
1.46
P/E (TTM)
8.2
EPS (TTM)
$0.27
52W Low $1.80High $3.22

Volume 0.27M

Average 0.78M

SPRO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Spero Therapeutics, Inc.NASDAQ: SPRO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $7.8M rose 11.4% year over year, behind the +410.9% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at -13.1% a year.

Context

  • Operating expenses amounted to 100.0% of revenue in FY2025, up 48.8 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +11.4% toward the trailing-twelve-month pace of +410.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.8M-5.5% QoQ
Last fiscal yearDec 2025
$59.64M+142.6% YoY
LTMMar 2026
$41.26M+410.9% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.4%——
1 year+142.6%——
3-year CAGR-13.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
59.64M USD
Year-over-year change
+142.6%
4-year CAGR
-10.0%

Operating Expenses vs competitors

How SPRO compares with its peers on the latest reported figures

  • SPRO's LTM Mar 2026 operating expenses of $41.26M is the 8th highest of the 10 companies compared; the peer median is $81.48M.
  • Its year-over-year change of +410.9% is the highest of 10, against a peer median of -16.0%.
  • Operating expenses amounts to 75.3% of revenue for SPRO, versus a peer median of 544.6%.
SPRO Competitors Peer median
Operating Expenses for SPRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$114.57M -9.5%+39.9%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$89.69M +109.1%+36.8%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$87.4M -16.0%-20.4%7620.1%
SEERSeer, Inc.LTM Mar 2026$81.9M -18.3%-6.5%544.6%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$81.48M -22.1%-32.1%—
IRDOpus Genetics, Inc.LTM Mar 2026$48.98M -30.2%+34.7%408.8%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$42.71M -20.4%+3.3%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$41.26M +410.9%-13.1%75.3%
HURATuHURA Biosciences, Inc.LTM Mar 2026$32.29M +72.1%+29.2%—
ACTUActuate Therapeutics IncLTM Mar 2026$21.83M -8.1%+3.6%—
Peer median (excluding SPRO) $81.48M-16.0%+3.6%544.6%

Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.07M48.58M103.78M47.98M59.62M
Cost of Revenue0051.44M96.76M0
Gross Profit3.07M48.58M52.34M(48.78M)59.62M
Gross Margin100.0%100.0%50.4%-101.7%100.0%
Research & Development64.53M47.59M51.44M96.76M38.47M
Selling, General & Admin41.7M36.48M25.55M23.7M21.18M
Operating Expenses91.04M90.78M30.86M24.58M59.64M
Depreciation & Amortization646K869K367K2K0
EBITDA(87.17M)(42.94M)27.15M(72.48M)8.83M
EBITDA Margin-2839.4%-88.4%26.2%-151.1%14.8%
Operating Income(87.97M)(42.2M)21.48M(73.36M)(24K)
Operating Margin-2865.5%-86.9%20.7%-152.9%-0.0%
Interest Income346K1.11M3.94M4.74M2.51M
Interest Expense1.94M2.61M000
Other Income / Expenses(1.79M)(4.22M)3.92M4.8M8.86M
Income Before Tax(89.76M)(46.42M)25.4M(68.57M)8.83M
Pre-Tax Margin-2923.6%-95.5%24.5%-142.9%14.8%
Income Tax Expense002.6M0261K
Net Income(89.76M)(46.42M)22.81M(68.57M)8.57M
Net Margin-2923.6%-95.5%22.0%-142.9%14.4%
EPS (Basic)(2.91)(1.23)0.43(1.27)0.15
EPS (Diluted)(2.91)(1.23)0.43(1.27)0.15
Weighted Avg Shares30.9M37.59M52.7M54.04M56.02M
Weighted Avg Shares (Diluted)30.9M37.59M52.99M54.04M59.04M

Spero Therapeutics, Inc.

NASDAQ:SPRO

Intrinsic Alpha fair value

Locked

Current Price

$0.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.